FDA Grants Priority Review to KTE-X19 for Treatment of Mantle Cell Lymphoma

The biologic license application is supported by data from the phase II ZUMA-2 trial, which is currently assessing the CAR T-cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

Source: CancerNetwork - February 10, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news